MetaCap

Cardio Diagnostics Holdings Inc. Company Profile

NASDAQ: CDIOHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

1.60-0.05 (-3.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Cardio Diagnostics at a glance

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company in the Health Care sector headquartered in Chicago, IL. Cardio Diagnostics is led by Dr. Meeshanthini V. Dogan Ph.D. and employs about 15 people. The company's shares have traded publicly since 2022.

At a market capitalization of $4.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001870144, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Cardio Diagnostics do?

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Business description based on the company's public filings.

Company information

Legal name
Cardio Diagnostics Holdings Inc.
Ticker
NASDAQ: CDIO
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Dr. Meeshanthini V. Dogan Ph.D.
Employees
15
Headquarters
311 West Superior Street, Chicago, IL, United States
Phone
855 226 9991
Website
cdio.ai
IPO year
2022
SEC CIK
0001870144
Latest annual report
10-K · Mar 13, 2026

Companies similar to Cardio Diagnostics

CDIO peer companies
CompanyPrice% ChgMarket capCompare
BMRABiomerica Inc.1.08-0.92%$4.97Mvs CDIO
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs CDIO
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs CDIO
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs CDIO
VRAXVirax Biolabs Group Limited0.3319-12.89%$446.40Kvs CDIO
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs CDIO
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs CDIO
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs CDIO

Related